Franck Lescure

General partner Bioseeds IV Auriga Partners

Franck Lescure is in charge of Life Sciences investments at AURIGA Partners. He manages the Fund AURIGA IV Bioseeds specialized in Infectiology and Microbiology and is directly involved in commitments of AURIGA Partners Funds in Amoéba (Euronext: AMEBA), Cytoo, EnobraQ, Erytech Pharma (Euronext: ERYP), Fab’entech, Flashcell, Pherecydes, Median Technologies (Alternext: ALMDT), Nosopharm and Pylote. Before Auriga Partners, Franck has been part as a scientist of the five initial years of Genset, one of the first French biotech startups, he has spent several years in the Air Liquide group and has been in charge of several investments as member of the Venture Capital team of Crédit Lyonnais Private Equity which became Omnes Capital. Franck is an alumnus of the Ecole Normale Supérieure and the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs.